---
title: "Key facts: Allogene ends Overland license; ALPHA3 58.3% MRD‑negativity"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286380061.md"
description: "Allogene (ALLO) has terminated its exclusive Overland license for cell therapies in several Asian countries, effective May 12, 2026, with no cash payment and equity reduced to approximately 3%. The company reported a 58.3% MRD negativity in its ALPHA3 Phase 2 trial and achieved RMAT designation for ALLO-316. In Q1 2026, Allogene posted a net loss of $42.6M with no revenue, but improved adjusted EPS. The company completed a $187.9M offering, extending its cash runway to 2029, while its stock saw a 5.7% decline in Q1 but a 67.9% increase year-to-date."
datetime: "2026-05-14T07:55:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286380061.md)
  - [en](https://longbridge.com/en/news/286380061.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286380061.md)
---

# Key facts: Allogene ends Overland license; ALPHA3 58.3% MRD‑negativity

-   Allogene (ALLO) ended its exclusive Overland license for cell therapies in China, Taiwan, South Korea and Singapore on May 12, 2026; no cash paid, equity reduced to ~3%, and governance deal updated.12
-   Allogene (ALLO): ALLO-316 earned RMAT; ALLO-329 got three Fast Track designations. Company expanding ALPHA3 global sites and set interim and final analyses dates.3
-   Allogene (ALLO) interim ALPHA3 Phase 2: cema-cel showed 58.3% MRD negativity vs 16.7% observation in 24 first‑line LBCL patients; favorable safety profile; expanded community access.45
-   Allogene (ALLO) Q1 2026: net loss $42.6M, adjusted EPS -$0.18 (improved YoY). No revenue. Cut R&D/G&A. Completed $187.9M offering, cash runway to 2029. Stock -5.7% Q1, +67.9% YTD.67

### Related Stocks

- [ALLO.US](https://longbridge.com/en/quote/ALLO.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)

## Related News & Research

- [Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)](https://longbridge.com/en/news/286408124.md)
- [Allogene Therapeutics - Enters Termination Agreement With Overland Therapeutics On May 12, 2026 - SEC Filing](https://longbridge.com/en/news/286315271.md)
- [Allogene Therapeutics ends China cell therapy deal with Overland](https://longbridge.com/en/news/286317303.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)